ClinicalTrials.gg
WithdrawnNCT05365100Updated Mar 24, 2023

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

A Phase 1/2 interventional study of BN102 in CLL/SLL and NHL, sponsored by BioNova Pharmaceuticals (Shanghai) LTD.. Withdrawn at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by BioNova Pharmaceuticals (Shanghai) LTD. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
Due to company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

Read the detailed description

The study is divided into 2 phases. Phase1 dose escalation part will enroll 17-36 patients to evaluate safety and tolerance of BN102 in patients with relapsed/refractory (R/R) CLL/SLL and B-NHL to determine maximum tolerated dose and recommended phase2 dose(RP2D).

Phase 2 expansion part will enroll 72-138 patients and be conducted at the selected dose level to further evaluate the safety and tolerability of BN102,as well as preliminary efficacy in specific subtypes of lymphoma. Patients will be allocated into 6 lymphoma subgroup cohorts depends on whether their previous treatment with or without BTK inhibitors.

  • Cohort 1: patients with mantle cell lymphoma (MCL) previously treated with BTK inhibitors
  • Cohort 2: patients with MCL who have not previously received a BTK inhibitor
  • Cohort 3: patients with CLL/SLL who have received prior BTK inhibitors
  • Cohort 4: patients with CLL/SLL who have not received prior BTK inhibitors
  • Cohort 5: other B-NHL patients who have received prior BTK inhibitors
  • Cohort 6: other B-NHL patients who have not received prior BTK inhibitors

Patients will receive orally administrated BN102 twice daily under fasting status. Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity, death, ICF withdraw ect. Subjects may receive study drug in the inpatient or outpatient setting.

02

Conditions studied

  • CLL/SLL
  • NHL

Browse trials for

Keywords

  • relapsed/refractory or intolerable
03

In context

Lead sponsor

BioNova Pharmaceuticals (Shanghai) LTD. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following conditions must be met for subject enrollment:

  • Have fully understood and voluntarily signed the form ;
  • Age ≥ 18 years;
  • In phase 1, subjects with confirmed CLL/SLL or B-cell NHL who are or intolerable after at least 1 prior line of adequate therapy, and have no better treatment choice as assessed by the investigator;
  • In Phase 2, the 6 cohorts had the following specific enrollment criteria and required further treatment:
  • Cohort 1: histologically confirmed MCL, failure or intolerance to at least one prior treatment including BTK inhibitor;
  • Cohort 2: histologically confirmed MCL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
  • Cohort 3: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
  • Cohort 4: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
  • Cohort 5: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
  • Cohort 6: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
  • In addition to CLL and WM, subjects must have at least one radiographically
  • score 0-2;
  • Male or female patients of must agree to use effective methods of

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system lymphoma or lymphoma involving the central nervous system;
  • Serological status reflects active viral (HBV) or viral (HCV) infection
  • infection;
  • Abnormalities in hematology lab results
  • Cardiac, hepatic, renal, and coagulation abnormalities
  • Concomitant systemic active infection uncontrollable after appropriate antibiotics or other treatment;
  • Expected survival of no more than 24 weeks as judged by the investigator;
  • Major surgery within 4 weeks prior to the first dose of study drug
  • Required or received anticoagulant therapy (warfarin, or equivalent vitamin K antagonist, or direct thrombin inhibitor, or factor Xa inhibitor, etc.) within 7 days prior to the first dose of study treatment;
  • Had undergone cell transplantation or chimeric antigen receptor T cell (CAR-T) therapy within 60 days prior to enrollment
  • Combined with uncontrolled active immune cytopenia
  • Previous treatment with non-covalently binding BTK inhibitors (e.g. LOXO-305, MK-1026, etc.);
  • Pregnant (positive pregnancy test at screening) or lactating female patients;
  • > 450 msec in male patients or QTcF > 470 msec in female patients or other significant abnormalities as judged by the investigator;
  • Toxicities due to prior antilymphoma therapy have not stabilized and have not recovered to ≤ Grade 1 (except for clinically insignificant toxicities such as alopecia, etc.);
  • History of other within 5 years prior to enrollment, special cases must be discussed with the medical monitor;
  • Prior systemic anti-tumor therapy or therapy received less than 4 weeks or 5 half-lives (whichever is shorter) from the start of the planned study treatment;
  • Use of strong inhibitors or inducers and proton pump inhibitors within 1 week or 5 half-lives (whichever is shorter) before administration of the first study drug;
  • History of acute myocardial infarction, unstable angina, stroke, intracranial hemorrhage or within 6 months prior to enrollment; (NYHA) grade 3 and 4 congestive heart failure;
  • Live viral vaccination within 28 days prior to the first dose of study drug;
  • Unable to take oral drugs, or have severe gastrointestinal diseases that investigator believes that it may affect the absorption of the study drug;
  • Insufficient compliance of patients participating in this clinical study as judged by the investigator;
  • Any other disease or condition in the judgment of the investigator that the patient is not suitable for the study drug, or will affect the interpretation of the study results
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase1dose escalation

    Phase1 Dose Escalation Multiple dose levels of BN102 to be evaluated; determination of MTD/Phase 2 recommended dose(RP2D)

    Drug: BN102

  • Experimental
    Phase2 expansion in R/R MCL with BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

  • Experimental
    Phase2 expansion in R/R MCL without BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should without BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

  • Experimental
    Phase2 expansion in R/R CLL/SLL with BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

  • Experimental
    Phase2 Expansion in R/R CLL/SLL without BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

  • Experimental
    Phase2 Expansion in other R/R B-NHL with BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should with BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

  • Experimental
    Phase2 Expansion in other R/R B-NHL without BTK inhibitor treatment history

    patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group

    Drug: BN102

Interventions

  • DrugBN102

    oral tablets: BN102, BID

    Also known as: AS-1763

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events and Clinical Laboratory Abnormalities

    Phase1

    Time frame: 2 year

  2. To assess the preliminary anti-tumor activity of BN102 based on Overall response rate(ORR) assessed by the Investigator

    Phase2

    Time frame: 3 years

Secondary outcomes

  1. Overall response rate(ORR) as assessed by the Investigator

    Phase1

    Time frame: 3 years

  2. Time to response(TTR) as assessed by the Investigator

    Phase1/2

    Time frame: 3 years

  3. Duration of response(DoR) as assessed by the Investigator

    Phase1/2

    Time frame: 3 years

  4. Progression-free survival(PFS) as assessed by the Investigator

    Phase1/2

    Time frame: 3 years

  5. Overall Survival(OS) as assessed by the Investigator

    Phase1/2

    Time frame: 3 years

  6. To characterized Maximum Plasma Concentration [Cmax] of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  7. To characterized Peak time(Tmax) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  8. To characterized Clearance half-life (T1/2) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  9. To characterized Area under the blood concentration-time curve (AUC0-t) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  10. To characterized Clearance rate (CL/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  11. To characterized apparent volume of distribution (Vd/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  12. To characterized mean residence time (MRT) of BN102 by collecting and evaluating the serum at the protocol specified time points.

    Phase1/2

    Time frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1

  13. Number of Participants with Adverse Events and Clinical Laboratory Abnormalities

    Phase2

    Time frame: 2 years

07

Study locations

6 sites
  • ZhuJiang Hospital of Southern Medical University
    Guangzhou, China
  • The First Affiliated School of Guangxi Medical University
    Nanning, China
  • Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
    Shanghai, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • Henan Oncology Hospital
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2022; primary completion for Jul 2024, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 9, 2022
StartEst.
Jul 2022
Primary completionEst.
Jul 30, 2024
CompletionEst.
Jul 30, 2024
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05365100
Lead sponsor
BioNova Pharmaceuticals (Shanghai) LTD.
Responsible party
Sponsor
First posted
May 9, 2022
Start date
Jul 2022 (estimated)
Primary completion
Jul 30, 2024 (estimated)
Completion
Jul 30, 2024 (estimated)
Last update
Mar 24, 2023

Study contacts

Weili Zhao, Prof.
principal investigator · Shanghai Jiaotong University school of Medicine, Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion